Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from REGN

This Foreboding Sign Looms Over Regeneron Pharmaceuticals's Chart

If history is any guide, there may be trouble ahead for shares of Regeneron Pharmaceuticals (NASDAQ:REGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.19% on an annualized basis producing an average annual return of 21.3%. Currently, Regeneron Pharmaceuticals has a market capitalization of $65.05 billion.

Benzinga

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis. Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data,…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Regeneron Pharmaceuticals Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 34 strange trades.

Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,800 Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.25% on an annualized basis producing an average annual return of 17.08%. Currently, Regeneron Pharmaceuticals has a market capitalization of $61.64 billion.

Benzinga

Regeneron Pharmaceuticals Whale Trades Spotted

Benzinga

7 Analysts Have This to Say About Regeneron Pharmaceuticals

Over the past 3 months, 7 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

United Airlines Leads Five Stocks Breaking Resistance As Market Rebounds

United Airlines headlines five stocks to watch for the week ahead. All are breaking resistance as the stock market rebounds.

Investors Business Daily

5 Large-Cap Stocks to Buy Amid the Nasdaq’s Bear Market

The stock market indices are regaining their lost ground, somewhat. However, the tech-heavy Nasdaq Composite remains in a bear market. Hence, we think the large-cap stocks of Comcast (CMCSA), Regeneron (REGN), Microsoft (MSFT), PepsiCo (PEP), and Sanofi (SNY) might be solid bets amid the market correction. Read on.

StockNews.com

Regeneron Pharmaceuticals Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q1 earnings of $973.50 million, an increase from Q4 of 56.33%. Sales dropped to $2.96 billion, a 40.13% decrease between quarters.

Benzinga

$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 19.7%. Currently, Regeneron Pharmaceuticals has a market capitalization of $72.59 billion.

Benzinga

Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased 17% to $2.96 billion, surpassing the analysts' consensus of $2.73 billion, fueled by sales of COVID-19 treatment, REGEN-COV. The company reported a net income of $974 million, down 13%, as its COVID-19…

Benzinga

Why The First Quarter Could Be A 'High-Water Mark' For Regeneron

The first quarter could represent a "high-water mark" for Regeneron Pharmaceuticals, an analyst said Wednesday.

Investors Business Daily

Regeneron Pharmaceuticals: Q1 Earnings Insights

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures: New Market Rally Awaits Fed Decision; AMD, Lithium Play Livent Jump Late

The major indexes rose slightly Tuesday, but stocks in these groups made bullish moves.

Benzinga

Earnings Preview: Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will report an earnings per share (EPS) of $10.04.

Benzinga

Where Regeneron Pharmaceuticals Stands With Analysts

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

Benzinga

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.58% on an annualized basis producing an average annual return of 18.92%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.02 billion.

StockNews.com

5 Outperforming Biotech Stocks with More Room to Run

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so far this year. Because this trend will likely continue, we think investing in popular biotech stocks Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Incyte Corp.…

Benzinga

FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy

The FDA has extended its review of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) marketing application of REGEN-COV (casirivimab and imdevimab) for non-hospitalized COVID-19 patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use. Regeneron has submitted additional data from its completed prophylaxis trial that the…

Benzinga

Analyst Ratings for Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:

Benzinga

This Is What Whales Are Betting On Regeneron Pharmaceuticals

Benzinga

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 11.29% on an annualized basis producing an average annual return of 18.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $77.02 billion.

Benzinga

Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneron

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) beefed up its gene therapy capabilities after signing a new deal with the German biotech ViGeneron. The companies did not specify their target but noted it would be some inherited retinal disease. It's an area where Regeneron has much expertise. One of its best-selling products, Eylea, is approved to treat…

1 2 3 4

People

Jerome Powell

2,709 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Microsoft Corporation

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.